Promore Pharma
9.11.2021 12:02:15 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 9, 2021 / Promore Pharma (STO:PROMO)(FRA:8T0)
Stockholm, November 9, 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announced today that the company has received approval from the Medical Products Agency and the Swedish Ethics Review Authority to begin a clinical phase II trial of ensereptide for skin scarring prevention.
The company announces today that a clinical trial permit has been obtained from the Medical Products Agency in Sweden and that the company's application for approval from the Ethical Review Authority has also been granted. PHSU05 is a Phase II pilot study with the aim of being able to evaluate ensereptide regarding (i) local tolerance, (ii) the application process of the experimental drug, and (iii) preliminary effect on scar prevention after experimentally induced wounds in healthy volunteers. Planned study start is Q1 2022 and results from the study are expected in the winter of 2022/2023.
"This is an important step in our long-term goal of developing a new product concept to prevent the occurrence of post-surgical and post-traumatic scars on the skin. These approvals are fully aligned with our operational plan in the ensereptide project ", says Jonas Ekblom, CEO of Promore Pharma.
Bolagets ensereptide-program fokuseras för närvarande på prevention av ärr i huden i samband med kirurgi eller trauma, men det finns även potential att utveckla produkten för andra medicinska applikationer som prevention av sammanväxning efter hand- och ryggradskirurgi.
The company's ensereptide program is currently focused on the prevention of scarring of the skin in connection with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of adhesions after surgeries in the hand or spine.
Scars develop after virtually all types of damage to the skin. Although scars can often be considered trivial, a large proportion of them can be disfiguring and aesthetically pleasing, and they can also create itching, stiffness, sleep problems, anxiety, depression and negatively affect activities of daily life.
The world market for products for the treatment of scars, including laser treatment, scar revision and self-care products, amounts to USD 25 billion with an annual growth of about 10%, according to independent estimates. Today, there are no prescription drugs for wound prevention.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
This information is information that Promore Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-09 11:38 CET.
Attachments
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/671849/Promore-Pharma-Receives-Permits-to-Start-a-Phase-II-Clinical-Trial-Regarding-Scar-Prevention
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
LiberNovo 2026 Chair Lineup Marks One Month on Sale as Early Bird Savings Enter Final Countdown15.7.2026 10:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / July 15, 2026 / The LiberNovo 2026 lineup, made up of the Omni SE, Omni Pro, and Maxis Series, has reached one month on sale, and its first-release early bird pricing has entered the final stretch. Offers end July 31 at 5:00 p.m. BST in the UK and 6:00 p.m. CEST across the EU. Orders placed before the deadline lock in launch pricing on every model. All three chairs are built on LiberNovo's dynamic support system, which keeps the backrest, neck support, seat, and armrests moving together as you shift, lean, and recline through five stages from 105° to 160°. Three Chairs, One Dynamic Support System The Omni SE keeps things simple. It runs on the same dynamic support, working mechanically with no motor or battery; you set the lumbar depth by hand and the chair does the rest. It ships in Obsidian at the most accessible price in the lineup. The Omni Pro is the premium chair in the lineup. Powered lumbar adjustment and the OmniStretch guided back stretch run
U.S. Polo Assn. Returns to 2026 DMMI Royal Charity Polo Cup as Official Apparel and Team Sponsor14.7.2026 13:00:00 CEST | Press release
Global Brand Supports Prince of Wales' Philanthropic Polo Event, Raising Over £1 Million WEST PALM BEACH, FL AND WINDSOR, UK / ACCESS Newswire / July 14, 2026 / U.S. Polo Assn.®, the global sports brand in partnership with Brand Machine Group (BMG), its licensing partner in the United Kingdom, proudly returned as the Official Apparel and Team Sponsor for the 2026 DMMI Royal Charity Polo Cup. The prestigious charitable event took place on July 10 at the historic Flemish Farm's Guards Polo Club in Windsor Great Park. 1) (left to right) U.S. Polo Assn. Team Accepts 2026 DMMI Royal Charity Polo Cup Trophy: Boo Jalil (BMG), Amr Zeden, Aiyawatt Srivaddhanaprahba, HRH The Princess of Wales, HRH The Prince of Wales, Mark Tomlinson, J. Michael Prince (USPA Global) 2) The 2026 DMMI Royal Charity Polo Cup in full swing at Flemish Farm's Guards Polo Club in Windsor Great Park 3) U.S. Polo Assn. Team Captain, HRH The Prince of Wales, riding a polo pony at the 2026 DMMI Royal Charity Polo Cup Photo
DYU Introduces SP1, a Folding E-Bike with a Removable Power Bank13.7.2026 11:05:00 CEST | Press release
Inspired by consumer-tech convergence, SP1 combines a lightweight 20-inch folding e-bike with a removable power source, AI Torque Sensor technology and mobile device charging. BERLIN, DE / ACCESS Newswire / July 13, 2026 / DYU, a global electric mobility brand focused on compact urban transportation, today announced the launch of the DYU SP1 20-inch Removable Power Bank Folding E-Bike, a lightweight model created for riders who need a more flexible way to move - and stay powered - throughout the day. First previewed at DYU's offline product launch event in Berlin last autumn, SP1 drew strong interest from attending media, partners and early users for its unusual combination of compact e-bike design and removable power bank functionality. Now officially available, SP1 brings that concept from launch-stage preview to real-world urban mobility. The inspiration behind SP1 comes from a simple but powerful product idea often associated with Steve Jobs: meaningful innovation can happen when f
Karbon-X Expands European Compliance Market Capabilities With Spanish EU ETS Registry Account9.7.2026 16:00:00 CEST | Press release
Milestone Strengthens Karbon-X's European Regulatory Infrastructure and Expands Its Operational Capabilities Within the World's Largest Compliance Carbon Market CALGARY, AB / ACCESS Newswire / July 9, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets and climate infrastructure, today announced the establishment of its European Union Emissions Trading System (EU ETS) Registry Account in Spain following regulatory approval from Spain's Office for Climate Change (Oficina Española de Cambio Climático). The milestone further strengthens the Company's regulatory infrastructure in Europe and marks another step in the continued execution of its European growth strategy. Following regulatory approval, the Company's EU ETS Registry Account has been established within the Spanish section of the Union Registry. Final technical activation by the Spanish Registry (RENADE) is expected shortly, aft
Parents Are Underestimating Their Kids' Digital Lives - Especially With AI: New Family Online Safety Institute Research9.7.2026 16:00:00 CEST | Press release
Survey of 4,000+ U.S. and Australian families finds children report doing more online - from social media to generative AI - than their parents realize. WASHINGTON, D.C. / ACCESS Newswire / July 9, 2026 / The Family Online Safety Institute (FOSI) today released Beyond Borders: U.S. and Australian Families on Online Safety, Screen Use, and the Digital Lives of Kids, the fourth wave of its bi-annual Online Safety Survey. When asked whether their child had used generative AI in the past week, 27% of parents said yes. When children were asked the same question about themselves, 38% said yes, an 11-point gap. The pattern held across nearly every online activity measured, including scrolling social media (46% of parents vs. 54% of children) and posting on social media (30% vs. 38%). Fielded in spring 2026 by Ipsos with more than 4,000 parents and children ages 10-17 across the United States and Australia, the research reveals a consistent and significant gap: children report doing more onlin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom